MiR-93 enhances angiogenesis and metastasis by targeting LATS2

Cell Cycle

Volumn 11, Issue 23, 2012, Pages 4352-4365

  Fang, Ling ^a,e   Du, William W ^a,e   Yang, Weining ^b   Rutnam, Zina Jeyapalan ^a,e   Peng, Chun ^b   Li, Haoran ^a,e   O'Malley, Yunxia Q ^c   Askeland, Ryan W ^c   Sugg, Sonia ^c   Liu, Mingyao ^d   Mehta, Tanvi ^a,e   Deng, Zhaoqun ^a,e   Yang, Burton B ^a,e  

^a Institute of Clinical Evaluative Sciences   (Canada)

^b YORK UNIVERSITY   (Canada)

^c UNIVERSITY OF IOWA   (United States)

^d UNIVERSITY HEALTH NETWORK   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

Author keywords

Angiogenesis; KPM; microRNA; siRNA; Tumorigenesis

Indexed keywords

MICRORNA; MIR 93; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CARCINOMA; CANCER CELL CULTURE; CELL ADHESION; COCULTURE; CONTROLLED STUDY; GENE EXPRESSION REGULATION; HUMAN; HUMAN TISSUE; LUNG METASTASIS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; PROTEIN FUNCTION; TUMOR VASCULARIZATION;

EID: 84870955164     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.22670     Document Type: Article

References (51)

1. Lee Y, Ahn C, Han J, Choi H, Kim J, Yim J, et al. The nuclear RNase III Drosha initiates microRNA processing. Nature 2003; 425:415-9; PMID:14508493; http://dx.doi.org/10.1038/nature01957.
2. Lai EC. Micro RNAs are complementary to 3′ UTR sequence motifs that mediate negative post-transcriptional regulation. Nat Genet 2002; 30:363-4; PMID:11896390; http://dx.doi.org/10.1038/ng865.
3. Lee DY, Shatseva T, Jeyapalan Z, Du WW, Deng Z, Yang BB. A 3′-untranslated region (3′UTR) induces organ adhesion by regulating miR-199a* functions. PLoS One 2009; 4:e4527; PMID:19223980; http://dx.doi.org/10.1371/journal.pone.0004527.
4. Jeyapalan Z, Deng Z, Shatseva T, Fang L, He C, Yang BB. Expression of CD44 3′-untranslated region regulates endogenous microRNA functions in tumorigenesis and angiogenesis. Nucleic Acids Res 2011; 39:3026-41; PMID:21149267; http://dx.doi.org/10.1093/nar/gkq1003.
5. Lee SC, Fang L, Wang CH, Kahai S, Deng Z, Yang BB. A non-coding transcript of nephronectin promotes osteoblast differentiation by modulating microRNA functions. FEBS Lett 2011; 585:2610-6; PMID:21784074; http://dx.doi.org/10.1016/j.febslet.2011.07.016.
6. Viticchiè G, Lena AM, Latina A, Formosa A, Gregersen LH, Lund AH, et al. MiR-203 controls proliferation, migration and invasive potential of prostate cancer cell lines. Cell Cycle 2011; 10:1121-31; PMID:21368580; http://dx.doi.org/10.4161/cc.10.7.15180.
7. Shatseva T, Lee DY, Deng Z, Yang BB. MicroRNA miR-199a-3p regulates cell proliferation and survival by targeting caveolin-2. J Cell Sci 2011; 124:2826-36; PMID:21807947; http://dx.doi.org/10.1242/jcs.077529.
8. Hidaka H, Seki N, Yoshino H, Yamasaki T, Yamada Y, Nohata N, et al. Tumor suppressive microRNA-1285 regulates novel molecular targets: aberrant expression and functional significance in renal cell carcinoma. Oncotarget 2012; 3:44-57; PMID:22294552.
9. Kahai S, Lee SC, Lee DY, Yang J, Li M, Wang CH, et al. MicroRNA miR-378 regulates nephronectin expression modulating osteoblast differentiation by targeting GalNT-7. PLoS One 2009; 4:e7535; PMID:19844573; http://dx.doi.org/10. 1371/journal.pone.0007535.
10. Luo L, Ye G, Nadeem L, Fu G, Yang BB, Honarparvar E, et al. MicroRNA-378a-5p promotes trophoblast cell survival, migration and invasion by targeting Nodal. J Cell Sci 2012; 125:3124-32; PMID:22454525; http://dx.doi.org/10.1242/jcs.096412.
11. Wang CH, Lee DY, Deng Z, Jeyapalan Z, Lee SC, Kahai S, et al. MicroRNA miR-328 regulates zonation morphogenesis by targeting CD44 expression. PLoS One 2008; 3:e2420; PMID:18560585; http://dx.doi.org/10.1371/journal.pone.0002420.
12. Shan SW, Lee DY, Deng Z, Shatseva T, Jeyapalan Z, Du WW, et al. MicroRNA MiR-17 retards tissue growth and represses fibronectin expression. Nat Cell Biol 2009; 11:1031-8; PMID:19633662; http://dx.doi.org/10.1038/ncb1917.
13. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A 2006; 103:2257-61; PMID:16461460; http://dx.doi.org/ 10.1073/pnas.0510565103.
14. Thomson JM, Newman M, Parker JS, Morin-Kensicki EM, Wright T, Hammond SM. Extensive post-transcriptional regulation of microRNAs and its implications for cancer. Genes Dev 2006; 20:2202-7; PMID:16882971; http://dx.doi.org/10.1101/ gad.1444406.
15. Nohata N, Hanazawa T, Enokida H, Seki N. microRNA-1/133a and microRNA-206/133b clusters: dysregulation and functional roles in human cancers. Oncotarget 2012; 3:9-21; PMID:22308266.
16. Fang L, Deng Z, Shatseva T, Yang J, Peng C, Du WW, et al. MicroRNA miR-93 promotes tumor growth and angiogenesis by targeting integrin-β8. Oncogene 2011; 30:806-21; PMID:20956944; http://dx.doi.org/10.1038/onc.2010.465.
17. Zou C, Xu Q, Mao F, Li D, Bian C, Liu LZ, et al. MiR-145 inhibits tumor angiogenesis and growth by N-RAS and VEGF. Cell Cycle 2012; 11:2137-45; PMID:22592534; http://dx.doi.org/10.4161/ cc.20598.
18. Lee DY, Deng Z, Wang CH, Yang BB. MicroRNA-378 promotes cell survival, tumor growth, and angiogenesis by targeting SuFu and Fus-1 expression. Proc Natl Acad Sci U S A 2007; 104:20350-5; PMID:18077375; http://dx.doi.org/10.1073/ pnas.0706901104.
19. Smits M, Nilsson J, Mir SE, van der Stoop PM, Hulleman E, Niers JM, et al. miR-101 is down-regulated in glioblastoma resulting in EZH2-induced proliferation, migration, and angiogenesis. Oncotarget 2010; 1:710-20; PMID:21321380.
20. Ma L, Teruya-Feldstein J, Weinberg RA. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 2007; 449:682-8; PMID:17898713; http://dx.doi.org/10.1038/nature06174.
21. Huang Q, Gumireddy K, Schrier M, le Sage C, Nagel R, Nair S, et al. The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis. Nat Cell Biol 2008; 10:202-10; PMID:18193036; http://dx.doi.org/10.1038/ncb1681.
22. Rutnam ZJ, Yang BB. The involvement of microRNAs in malignant transformation. Histol Histopathol 2012; 27:1263-70; PMID:22936445.
23. Ory B, Ellisen LW. A microRNA-dependent circuit controlling p63/p73 homeostasis: p53 family cross-talk meets therapeutic opportunity. Oncotarget 2011; 2:259-64; PMID:21436470.
24. Yang X, Rutnam ZJ, Jiao C, Wei D, Xie Y, Du J, et al. An anti-let-7 sponge decoys and decays endogenous let-7 functions. Cell Cycle 2012; 11:3097-108; PMID:22871741; http://dx.doi.org/10.4161/cc.21503.
25. Yang W, Lee DY, Ben-David Y. The roles of microRNAs in tumorigenesis and angiogenesis. Int J Physiol Pathophysiol Pharmacol 2011; 3:140-55; PMID:21760972.
26. Altuvia Y, Landgraf P, Lithwick G, Elefant N, Pfeffer S, Aravin A, et al. Clustering and conservation patterns of human microRNAs. Nucleic Acids Res 2005; 33:2697-706; PMID:15891114; http://dx.doi.org/10.1093/nar/gki567.
27. Koralov SB, Muljo SA, Galler GR, Krek A, Chakraborty T, Kanellopoulou C, et al. Dicer ablation affects antibody diversity and cell survival in the B lymphocyte lineage. Cell 2008; 132:860-74; PMID:18329371; http://dx.doi.org/10. 1016/j.cell.2008.02.020.
28. Sylvestre Y, De Guire V, Querido E, Mukhopadhyay UK, Bourdeau V, Major F, et al. An E2F/miR-20a autoregulatory feedback loop. J Biol Chem 2007; 282:2135-43; PMID:17135249; http://dx.doi.org/10.1074/jbc.M608939200.
29. Mendell JT. miRiad roles for the miR-17-92 cluster in development and disease. Cell 2008; 133:217-22; PMID:18423194; http://dx.doi.org/10.1016/j.cell. 2008.04.001.
30. Bonauer A, Dimmeler S. The microRNA-17-92 cluster: still a miRacle? Cell Cycle 2009; 8:3866-73; PMID:19887902; http://dx.doi.org/10.4161/ cc.8.23.9994.
31. Matsubara H, Takeuchi T, Nishikawa E, Yanagisawa K, Hayashita Y, Ebi H, et al. Apoptosis induction by anti-sense oligonucleotides against miR-17-5p and miR-20a in lung cancers overexpressing miR-17-92. Oncogene 2007; 26:6099-105; PMID:17384677; http://dx.doi.org/10.1038/sj.onc.1210425.
32. Hayashita Y, Osada H, Tatematsu Y, Yamada H, Yanagisawa K, Tomida S, et al. A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. Cancer Res 2005; 65:9628-32; PMID:16266980; http://dx.doi.org/10.1158/0008-5472.CAN-05-2352.
33. Mendell JT. MicroRNAs: critical regulators of development, cellular physiology and malignancy. Cell Cycle 2005; 4:1179-84; PMID:16096373; http://dx.doi.org/10.4161/cc.4.9.2032.
34. Landais S, Landry S, Legault P, Rassart E. Oncogenic potential of the miR-106-363 cluster and its implication in human T-cell leukemia. Cancer Res 2007; 67:5699-707; PMID:17575136; http://dx.doi.org/10.1158/0008-5472.CAN-06- 4478.
35. Ventura A, Young AG, Winslow MM, Lintault L, Meissner A, Erkeland SJ, et al. Targeted deletion reveals essential and overlapping functions of the miR-17 through 92 family of miRNA clusters. Cell 2008; 132:875-86; PMID:18329372; http://dx.doi.org/10.1016/j.cell.2008.02.019.
36. Dang CV. MYC, microRNAs and glutamine addiction in cancers. Cell Cycle 2009; 8:3243-5; PMID:19806017; http://dx.doi.org/10.4161/cc.8.20.9522.
37. Li Y, Tan W, Neo TW, Aung MO, Wasser S, Lim SG, et al. Role of the miR-106b-25 microRNA cluster in hepatocellular carcinoma. Cancer Sci 2009; 100:1234-42; PMID:19486339; http://dx.doi.org/10.1111/ j.1349-7006.2009.01164.x.
38. Yeung ML, Yasunaga J, Bennasser Y, Dusetti N, Harris D, Ahmad N, et al. Roles for microRNAs, miR-93 and miR-130b, and tumor protein 53-induced nuclear protein 1 tumor suppressor in cell growth dysregulation by human T-cell lymphotrophic virus 1. Cancer Res 2008; 68:8976-85; PMID:18974142; http://dx.doi.org/10.1158/0008-5472.CAN-08-0769.
39. Du L, Schageman JJ, Subauste MC, Saber B, Hammond SM, Prudkin L, et al. miR-93, miR-98, and miR-197 regulate expression of tumor suppressor gene FUS1. Mol Cancer Res 2009; 7:1234-43; PMID:19671678; http://dx.doi.org/10.1158/1541- 7786.MCR-08-0507.
40. Mu P, Han YC, Betel D, Yao E, Squatrito M, Ogrodowski P, et al. Genetic dissection of the miR-17~92 cluster of microRNAs in Myc-induced B-cell lymphomas. Genes Dev 2009; 23:2806-11; PMID:20008931; http://dx.doi.org/10.1101/ gad.1872909.
41. Visser S, Yang X. LATS tumor suppressor: a new governor of cellular homeostasis. Cell Cycle 2010; 9:3892-903; PMID:20935475; http://dx.doi.org/10. 4161/ cc.9.19.13386.
42. Li Y, Pei J, Xia H, Ke H, Wang H, Tao W. Lats2, a putative tumor suppressor, inhibits G1/S transition. Oncogene 2003; 22:4398-405; PMID:12853976; http://dx.doi.org/10.1038/sj.onc.1206603.
43. rd, Fernandes MJ, McCollum D. Angiomotin family proteins are novel activators of the LATS2 kinase tumor suppressor. Mol Biol Cell 2011; 22:3725-33; PMID:21832154; http://dx.doi.org/10.1091/mbc.E11-04-0300.
44. Cornils H, Kohler RS, Hergovich A, Hemmings BA. Downstream of human NDR kinases: impacting on c-myc and p21 protein stability to control cell cycle progression. Cell Cycle 2011; 10:1897-904; PMID:21593588; http://dx.doi.org/10. 4161/ cc.10.12.15826.
45. Aylon Y, Michael D, Shmueli A, Yabuta N, Nojima H, Oren M. A positive feedback loop between the p53 and Lats2 tumor suppressors prevents tetraploidization. Genes Dev 2006; 20:2687-700; PMID:17015431; http://dx.doi.org/10.1101/gad.1447006.
46. Yabuta N, Mukai S, Okada N, Aylon Y, Nojima H. The tumor suppressor Lats2 is pivotal in Aurora A and Aurora B signaling during mitosis. Cell Cycle 2011; 10:2724-36; PMID:21822051; http://dx.doi.org/10.4161/cc.10.16.16873.
47. Tschöp K, Conery AR, Litovchick L, Decaprio JA, Settleman J, Harlow E, et al. A kinase shRNA screen links LATS2 and the pRB tumor suppressor. Genes Dev 2011; 25:814-30; PMID:21498571; http://dx.doi.org/10.1101/gad.2000211.
48. Rutnam ZJ, Yang BB. The non-coding 3′ UTR of CD44 induces metastasis by regulating extracellular matrix functions. J Cell Sci 2012; 125:2075-85; PMID:22637644.
49. Wu QP, Xie YZ, Deng Z, Li XM, Yang W, Jiao CW, et al. Ergosterol Peroxide Isolated from Ganoderma lucidum Abolishes MicroRNA miR-378-Mediated Tumor Cells on Chemoresistance. PLoS One 2012; 7:e44579; PMID:22952996; http://dx.doi.org/10.1371/journal.pone.0044579.
50. LaPierre DP, Lee DY, Li SZ, Xie YZ, Zhong L, Sheng W, et al. The ability of versican to simultaneously cause apoptotic resistance and sensitivity. Cancer Res 2007; 67:4742-50; PMID:17510402; http://dx.doi.org/10.1158/0008-5472.CAN- 06-3610.
51. Yee AJ, Akens M, Yang BL, Finkelstein J, Zheng PS, Deng Z, et al. The effect of versican G3 domain on local breast cancer invasiveness and bony metastasis. Breast Cancer Res 2007; 9:R47; PMID:17662123; http://dx.doi.org/10. 1186/bcr1751.